Han et al. showed that MYC inhibition upregulated PD-L1 expression on tumor cells and increased the number of CD3+, CD4+, and CD8+ T-cells, thereby sensitizing otherwise refractory tumors for ICI treatment [43]. The gene discussed is CD8A; the disease is neoplasm.